Month: May 2023

A bibliometric review on vitamins and Alzheimer’s disease between 1996 and 2023

Objective: Alzheimer’s disease (AD) is a major disease that affects the elderly worldwide. Several studies have revealed that vitamins may influence the risk of developing AD. However, information in this field remains ambiguous. Therefore, this study aimed to examine the relationship between AD and vitamins, identify journal publications and collaborators, and analyze keywords and research […]

Published on May 11, 2023

Editorial: Exploring reliable markers and prediction indexes for the progression from subjective cognitive decline to cognitive impairment, volume II

Read Full Article (External Site) Dr. David LowemannDr. David Lowemann, M.Sc, Ph.D., is a co-founder of the Institute for the Future of Human Potential, where he leads the charge in pioneering Self-Enhancement Science for the Success of Society. With a keen interest in exploring the untapped potential of the human mind, Dr. Lowemann has dedicated […]

Published on May 11, 2023

FDA Approves First Alzheimer’s Agitation Drug

The U.S. Food and Drug Administration approved Otsuka Pharmaceutical’s brexpiprazole to treat agitation in patients with Alzheimer’s on Thursday, making it the first approved drug for the indication, the company said in a statement. The decision comes after an advisory panel… Read Full Article (External Site) Dr. David LowemannDr. David Lowemann, M.Sc, Ph.D., is a […]

Published on May 11, 2023